drugset / Trial / NCT06342037
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced triple-negative breast cancer.
Timeline
- Start
- 2024-06-12
- Primary completion
- 2026-04-01
- Completion
- 2030-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | — |
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Tiragolumab | Monoclonal antibody | 600 mg | — |